Audrey McAlpine
Impact in
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
-
- Antibiotic Use and Resistance
Papers in
-
- SARS-CoV-2 and COVID-19 Research 3
-
- Machine Learning in Bioinformatics 1
- RNA and protein synthesis mechanisms 1
- Partner nations
- United KingdomAustraliaItaly
In The Last Decade
Audrey McAlpine
8 papers receiving 1.5k citations
Audrey McAlpine's Hit Papers
Peers
Comparison fields: 5 of 99
- Infectious Diseases 968
- Applied Microbiology and Biotechnology 50
- Neurology 341
- Internal Medicine 56
- Obstetrics and Gynecology 85
Countries citing papers authored by Audrey McAlpine
This map shows the geographic impact of Audrey McAlpine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Audrey McAlpine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Audrey McAlpine more than expected).
Fields of papers citing papers by Audrey McAlpine
This network shows the impact of papers produced by Audrey McAlpine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Audrey McAlpine. The network helps show where Audrey McAlpine may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 403 |
| 2 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 381 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 230 |
| 5 | Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 211 |
| 6 | 2023 | 83 | |
| 7 | 2021 | 24 | |
| 8 | 2025 | 2 |
About Audrey McAlpine
Audrey McAlpine is a scholar working on Infectious Diseases, Molecular Biology, Insect Science, Renewable Energy, Sustainability and the Environment and Obstetrics and Gynecology, having authored 8 papers that have together received 1.6k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (3 papers), Machine Learning in Bioinformatics (1 paper) and RNA and protein synthesis mechanisms (1 paper). The work is most often cited by research in Infectious Diseases (968 citations), Applied Microbiology and Biotechnology (50 citations), Neurology (341 citations), Internal Medicine (56 citations) and Obstetrics and Gynecology (85 citations). Audrey McAlpine has collaborated with scholars based in United Kingdom, Australia and Italy. Their work appears in journals such as The Lancet, EClinicalMedicine and Human Genetics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.